Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue: 2021-2025

Historic Current Deferred Revenue for ARS Pharmaceuticals (SPRY) over the last 1 years, with Sep 2025 value amounting to $526,000.

  • ARS Pharmaceuticals' Current Deferred Revenue was N/A to $526,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $526,000, marking a year-over-year change of. This contributed to the annual value of $557,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Current Deferred Revenue is $526,000, which was down 29.49% from $746,000 recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Current Deferred Revenue registered a high of $3.1 million during Q4 2022, and its lowest value of $10,000 during Q1 2023.
  • Over the past 3 years, ARS Pharmaceuticals' median Current Deferred Revenue value was $540,000 (recorded in 2025), while the average stood at $475,800.
  • Data for ARS Pharmaceuticals' Current Deferred Revenue shows a peak YoY surged of 115.31% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Current Deferred Revenue stood at $1.5 million in 2021, then surged by 115.31% to $3.1 million in 2022, then reached $10,000 in 2023, then reached $557,000 in 2024, then reached $526,000 in 2025.
  • Its Current Deferred Revenue was $526,000 in Q3 2025, compared to $746,000 in Q2 2025 and $540,000 in Q1 2025.